SCHEMBL3773875

SCHEMBL3773875

COC[C@H]1OC[C@@](NC(=S)NC(=O)c2ccccc2)(c2ccccc2F)[C@H]1CO

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
ALDH1A1 P00352 11/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
ALOX12 P18054 5/20 0.36
LMNA P02545 4/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 1/20 0.36
GLA P06280 2/20 0.36
RECQL P46063 1/20 0.34
GAA P10253 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2619901 1.00 EPHX1 (0.39) EPHX1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2108331 1.00 EPHX1 (0.39) EPHX1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2631696 1.00 EPHX1 (0.39) EPHX1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL18032972 0.90 BACE1 (0.36) EPHX1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2108797 0.90 EPHX1 (0.41) EPHX1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2108798 0.90 EPHX1 (0.41) EPHX1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL8034193 0.90 EPHX1 (0.41) EPHX1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL11293044 0.89 EPHX1 (0.42) EPHX1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3773247 0.88 EPHX1 (0.37) EPHX1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2632297 0.88 EPHX1 (0.37) EPHX1SMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317850-A1 CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317850-A1 CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE BACE1, APP, BACE2 EPHX1 2197/4885SMN1; SMN2 857/4885ALDH1A1 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.